IP Library Granted Patent US 6,926,710
Granted Patent B2
US 6,926,710 · App. 10/045,694 · Granted Aug 9, 2005

Method and system for improving vision

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,926,710
App. No.
10/045,694
Granted
Aug 9, 2005
Kind
B2
Abstract

Methods and apparatus for improving vision incorporate the effects of biodynamical and biomechanical (biological) responses of the eye. The eye produces a biological response to trauma, such as a LASIK keratectomy or other necessary traumatic procedure in preparation for refractive surgery. By observing the biological response, a prospective treatment to correct higher order aberrations is adjusted to compensate for the biological effects. An improved photorefractive surgery system incorporates one or more suitable diagnostic devices that provide biological response information in such a manner that the patient need not change position from that assumed for the surgical procedure.

Claims (25)

1. A method for correcting for higher order aberrations of a patient's eye, comprising:

inflicting a required surgical trauma to the eye corresponding to a particular ophthamological procedure;

obtaining diagnostic wavefront information subsequent to inflicting the trauma;

developing a treatment for correcting the higher order aberrations of the patient's eye based at least in part upon the subsequent wavefront information.

2. The method of claim 1 , wherein the surgical trauma includes at least one of a lamellar corneal cut, a keratectomy, a keratotomy, a corneal abrasion, a corneal puncture, a corneal incision.

3. The method of claim 2 , wherein said trauma is a keratome cut to create a LASIK flap and further wherein said diagnostic wavefront information is obtained prior to lifting said flap.

4. The method of claim 1 , wherein developing the treatment comprises considering a biodynamical effect in response to the trauma, further wherein said subsequent wavefront information includes indicia of said biodynamical effect.

5. The method of claim 4 , wherein developing the treatment includes determining an ablation profile that is adjusted with respect to a prospective ablation profile associated with correcting the higher order aberrations in the absence of considering the biodynamical effect in response to the trauma.

6. The method of claim 5 , wherein said adjustment is an empirical based adjustment.

7. The method of claim 1 , further comprising obtaining a diagnostic measurement of the patient's eye prior to inflicting the surgical trauma.

8. The method of claim 7 , further comprising using said prior diagnostic information and said subsequent wavefront information to develop said treatment.

9. The method of claim 1 , wherein said subsequent wavefront information is obtained at a time after the infliction of the surgical trauma ranging from substantially immediately to an empirically or diagnostically determined time in consideration of a biodynamic effect of the eye in response to the surgical trauma.

10. The method of claim 9 , wherein said determined time is within one month of said trauma infliction.

11. The method of claim 1 , wherein said obtained wavefront information is at least one of a direct wavefront measurement or derived from a non-direct wavefront measurement.

12. The method of claim 1 , further comprising:

considering a prospective biomechanical effect of the eye with respect to the developed treatment; and

adjusting said developed treatment, at least in part, as a function of the prospective biomechanical effect of the eye.

13. The method of claim 1 , further comprising obtaining a different diagnostic measurement indicative of a characteristic of the epithelium of the eye, and using information from this measurement to adjust the developed treatment to compensate for a biomechanical effect of the eye.

14. The method of claim 13 , wherein said epithelium characteristic includes at least one of an epithelial profile and epithelial thickness.

15. The method of claim 1 , further comprising treating the eye.

16. The method of claim 15 , wherein after said treatment, the sum total of rotationally symmetric aberrations is equal to or greater than a sum total of rotationally asymmetric aberrations.

17. The method of claim 15 , comprising performing a photoablative treatment with a laser beam having a diameter, d, at a target location between 0.5 mm≦d≦7 mm.

18. The method of claim 15 , wherein said treatment includes at least one of photo-ablation and a corneal inlay.

19. The method of claim 18 , comprising performing a photoablative treatment with a laser beam having a diameter, d, at a target location between 0.5 mm≦d≦7 mm.

20. The method of claim 1 , wherein said diagnostic wavefront information is obtained by a measurement made through a line of sight of the patient's eye.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →